The Second Generation Type II JAK2 Inhibitor, AJ1-10502, Demonstrates Enhanced Selectivity, Improved Therapeutic Efficacy and Reduced Mutant Cell Fraction Compared to Type I JAK2 Inhibitors in Models of Myeloproliferative Neoplasms (MPNs)
| Autor: | Rai, Shivam *, Stetka, Jan *, Usart, MARC *, Hao-Shen, Hui *, Park, Young *, Houston, Remie *, Martinez Benitez, Anthony R. *, Wereski, Matthew *, Guzzardi, Emily *, Persaud, Sonali *, Ramzan, Hailey *, Futran, Alan *, Xu, Charley *, Greenwood, Jeremy *, Mondal, Sayan *, Masse, Craig *, Levine, Ross L., Skoda, Radek C., Dunbar, Andrew |
|---|---|
| Zdroj: | In Blood 15 November 2022 140 Supplement 1:6722-6723 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|